Profile data is unavailable for this security.
About the company
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
- Revenue in USD (TTM)243.90m
- Net income in USD-283.87m
- Incorporated1999
- Employees597.00
- LocationRevance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
- Phone+1 (615) 724-7755
- Fax+1 (302) 655-5049
- Websitehttps://www.revance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | 62.02m | -45.65m | 391.87m | 99.00 | -- | 2.02 | -- | 6.32 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Elite Pharmaceuticals Inc | 66.45m | 19.58m | 398.44m | 64.00 | 19.50 | 6.84 | 18.92 | 6.00 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| CorMedix Inc | 806.12k | -53.12m | 412.25m | 82.00 | -- | 8.83 | -- | 511.40 | -0.9262 | -0.9262 | 0.0141 | 0.8355 | 0.014 | -- | -- | 9,830.73 | -92.57 | -54.84 | -110.35 | -62.32 | -64.79 | 6.18 | -6,589.09 | -18,323.42 | 4.43 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Zevra Therapeutics Inc | 23.99m | -65.75m | 424.10m | 65.00 | -- | 10.42 | -- | 17.68 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 436.57m | 377.00 | -- | -- | -- | 2.41 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 453.33m | 150.00 | -- | 2.62 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Aquestive Therapeutics Inc | 58.36m | -25.72m | 463.49m | 135.00 | -- | -- | -- | 7.94 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Eyepoint Pharmaceuticals Inc | 50.39m | -86.82m | 476.85m | 121.00 | -- | 2.04 | -- | 9.46 | -1.80 | -1.80 | 1.08 | 4.38 | 0.2016 | 1.10 | 8.18 | 416,454.50 | -34.74 | -40.44 | -47.07 | -47.79 | 91.35 | 83.45 | -172.29 | -186.23 | 4.69 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| SNDL Inc | 672.06m | -83.20m | 527.50m | 2.52k | -- | 0.5812 | -- | 0.7849 | -0.3185 | -0.3185 | 2.56 | 3.42 | 0.5988 | 4.63 | 33.15 | 267,115.60 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| SIGA Technologies Inc | 172.96m | 83.97m | 601.64m | 45.00 | 7.25 | 3.59 | 7.12 | 3.48 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Revance Therapeutics Inc | 243.90m | -283.87m | 605.29m | 597.00 | -- | -- | -- | 2.48 | -3.17 | -3.21 | 2.64 | -1.24 | 0.4466 | 1.35 | 9.18 | 408,542.70 | -51.97 | -55.55 | -61.40 | -63.20 | 71.53 | -- | -116.39 | -304.96 | 3.01 | -22.09 | 1.41 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Pacira Biosciences Inc | 690.31m | 63.59m | 670.22m | 711.00 | 12.42 | 0.7621 | 4.86 | 0.9709 | 1.17 | 1.17 | 12.34 | 19.07 | 0.4329 | 1.83 | 6.77 | 970,900.10 | 3.99 | 3.35 | 4.26 | 3.98 | 74.05 | 72.63 | 9.21 | 8.57 | 5.70 | -- | 0.4013 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Pliant Therapeutics Inc | 0.00 | -185.41m | 738.13m | 158.00 | -- | 1.87 | -- | -- | -3.09 | -3.09 | 0.00 | 6.50 | 0.00 | -- | -- | 0.00 | -35.03 | -33.24 | -37.15 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0711 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Avid Bioservices Inc | 142.36m | -144.17m | 740.02m | 371.00 | -- | 12.62 | -- | 5.20 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| Liquidia Corp | 14.84m | -112.11m | 835.79m | 136.00 | -- | 12.12 | -- | 56.32 | -1.57 | -1.57 | 0.2102 | 0.8208 | 0.0993 | -- | 4.04 | 109,117.60 | -75.00 | -55.02 | -87.85 | -62.69 | 69.52 | 82.18 | -755.46 | -474.59 | 5.78 | -29.47 | 0.578 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Data as of Sep 23 2024. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD
52.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 13.95m | 13.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.55m | 6.27% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 6.24m | 5.98% |
| GIC Pte Ltd. (Investment Management)as of 08 Mar 2024 | 5.83m | 5.58% |
| Palo Alto Investors LPas of 31 Mar 2024 | 5.25m | 5.02% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.17m | 4.95% |
| Polar Capital LLPas of 31 Mar 2024 | 3.88m | 3.72% |
| Barclays Capital, Inc.as of 31 Mar 2024 | 2.92m | 2.80% |
| Rubric Capital Management LPas of 31 Mar 2024 | 2.66m | 2.54% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.36m | 2.26% |
More ▼
Data from 31 Mar 2024 - 01 Aug 2024Source: FactSet Research Systems Inc.
